Special Issue "Medical Advances in Viral Hemorrhagic Fever Research"
Deadline for manuscript submissions: closed (31 July 2019).
Interests: emerging infectious diseases; viral hemorrhagic fevers; mechanisms of immune privilege and viral persistence; filoviruses; arenaviruses
Interests: arenaviruses; biodefense; bioengagement; BSL-4; filoviruses; henipaviruses; Kyasanur Forest disease virus; nairoviruses; phleboviruses; Omsk hemorrhagic fever virus; simian hemorrhagic fever virus
Special Issues, Collections and Topics in MDPI journals
Topical Collection in Viruses: Advances in Ebolavirus, Marburgvirus, and Cuevavirus Research
Interests: molecular virology; emerging infectious diseases; viral hemorrhagic fevers; arenaviruses; filoviruses; alphaviruses
Recent large outbreaks of Ebola and Marburg virus disease (Eastern and Western Africa), Lassa fever (Western Africa), Crimean Congo hemorrhagic fever (Africa, Eastern Europe, Western Asia) and severe fever with thrombocytopenia syndrome (China, Japan, South Korea) have afforded higher-resolution views at human clinical diseases historically referred to as “viral hemorrhagic Fevers.” In addition to updating our understanding of the spectrum and severity of acute disease syndromes, recent encounters have renewed interest in, e.g., the role of pathogen–agnostic care in addition to virus-specific countermeasures, clinical sequelae after infection, and viral persistence potentially associated with inflammatory syndromes or risk of transmission and outbreak re-ignition. Although there are no FDA-approved medical countermeasures against these viral agents, increased funding, interest, and novel technologies have accelerated research and understanding of many medical aspects of these and other, more neglected (e.g., Alkhurma, Chapare, Guanarito, Kyasanur Forest disease, Lujo, Omsk hemorrhagic fever, Sabiá viruses), viral hemorrhagic fever-causing pathogens. New clinical data and at-bedside approached, advanced genomics and proteomics tools, CRISPR-Cas9 screens, and novel off-label or IND-level vaccine and therapeutics platforms have all contributed (or have the potential) to expand our knowledge of disease course, pathogenesis, and molecular epidemiology, as well as to the development of better diagnostics and medical countermeasures. The present Special Issue covers a wide range of topics focusing on human clinical disease related to such “Medical Advances in Viral Hemorrhagic Fever Research".
Dr. Ian Crozier
Dr. Jens H. Kuhn
Dr. Sheli R. Radoshitzky
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- clinical presentation
- epidemiology/outbreak response
- medical countermeasures